"10.1371_journal.pone.0094821","plos one","2014-04-17T00:00:00Z","Andrea Fuhs; Dunya Bentama; Rafael Antkowiak; Johannes Mathis; Claudia Trenkwalder; Klaus Berger","Institute of Epidemiology and Social Medicine, University of Muenster, Muenster, Germany; Department of Neurology, Inselspital, Bern University Hospital, Bern, Switzerland; Department of Neurology, Paracelsus-Elena-Klinik Kassel, Kassel, Germany","Conceived and designed the experiments: CT KB. Performed the experiments: AF DB KB RA. Analyzed the data: AF KB. Contributed reagents/materials/analysis tools: AF JM DB CT KB RA. Wrote the paper: AF JM DB CT KB. Interpretation of the results: AF JM CT KB.","Andrea Fuhs, Dunya Bentama and Rafael Antkowiak have declared that no competing interests exist. This study was funded from a consortium formed by Boeringer Ingelheim Pharma, Mundipharma Research, Neurobiotec, Roche Pharma, UCB (Germany + Switzerland) and Vifor Pharma. Johannes Mathis was paid by Boehringer Ingelheim for a speaking engagement and the Swiss RLS patient association of whom he is the president was supported by Boehringer Ingelheim, Glaxo-Smith Kline and UCB with less than $10,000 as unrestricted grant. Full disclosure for Klaus Berger: Dr. Berger has received within the last 5 years completely investigator-initiated research funding as principal or coordinating investigator in the areas of stroke, depression and subclinical atherosclerosis, diabetes, multiple sclerosis and multimorbidity and health services research from the German Minister of Research and Technology (BMBF). For the conduction (2003â€“2007) of a study on regional variations of migraine and other types of headache he has received unrestricted grants of equal share to the University of Muenster from the German Migraine and Headache Society (DMKG) and Allmiral, Astra-Zeneca, Berlin-Chemie, Boehringer Ingelheim Pharma, Boots Healthcare, GlaxoSmithKline, Janssen Cilag, McNeil Pharmaceuticals, MSD Sharp & Dohme, Pfizer. Claudia Trenkwalder: has received speakers' honoraria from UCB, Glaxo SmithKline, Novartis, Boehringer Ingelheim and consulting fees from Britannia, UCB, Novartis, Mundipharm and Orion. She has received unrestricted research grants from TEVA and Mundipharm, and ongoing research support from the Michael J. Fox Foundation. There are no patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.","2014","04","Andrea Fuhs","AF",6,FALSE,2,4,2,5,TRUE,TRUE,FALSE,0,NA,FALSE
